Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today

Page 1 of 2

The markets are off to a rocking start this week on the back of growing optimism after a strong jobs report on Friday, and waning uncertainty around the global economy after Japanese Prime Minister Shinzo Abe’s party won a supermajority in the country’s upper house elections this weekend, as well as the emergence of a sole candidate, Theresa May, to replace U.K PM David Cameron.

Investors are paying close attention to a handful of stocks today, including Coherus Biosciences Inc (NASDAQ:CHRS), Hortonworks Inc (NASDAQ:HDP), Organovo Holdings Inc (NYSEMKT:ONVO), Hi-Crush Partners LP (NYSE:HCLP), and Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS). Let’s find out why these stocks are in the spotlight today and also see how hedge funds in our database are positioned in them.

Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that imitating the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012 (read more details here).

computers, work,

Tonis Valing / Shutterstock.com

Coherus Biosciences’ Successful Study

Coherus Biosciences Inc (NASDAQ:CHRS) has skyrocketed by more than 9% today after the company revealed that its CHS-1701 (pegfilgrastim biosimilar candidate) pharmacokinetic and pharmacodynamic biosimilarity study met all of its co-primary endpoints. In a statement, Coherus Biosciences’ Chief Medical Officer Barbara Finck said that given the results from the study, the company is confident that CHS-1701 is highly biosimilar to the reference product, Neulasta, and will produce the expected clinical effect in patients. 11 hedge funds in our system were bullish on Coherus Biosciences Inc (NASDAQ:CHRS) at the end of the first quarter.

Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Trade (NASDAQ:CHRS) Now!

DA Davidson Upgrades Hortonworks

Shares of Hortonworks Inc (NASDAQ:HDP) have soared by 8.80% today after analysts at investment company DA Davidson upgraded the company to ‘Buy’ from ‘Neutral’ in a report issued to investors on Monday. The firm currently has a price target of $13 on the California-based software company. Hortonworks released its most recent quarterly financial results in May, which met analysts’ estimates. John Burbank’s Passport Capital is one of the 13 hedge funds in our system with stakes in Hortonworks Inc (NASDAQ:HDP) as of the end of the first quarter.

Follow Hortonworks Inc. (NASDAQ:HDP)
Trade (NASDAQ:HDP) Now!

On the next page we’ll discuss the latest news concerning Hi-Crush Partners, Kratos Defense & Security Solutions, and Organovo Holdings.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!